Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

CEA-Scan (Immunomedics Inc): Full Drug Profile

Medically reviewed by Dr. Otari Nergadze, Neurosurgeon | Updated: January 2026

CEA-Scan (Immunomedics Inc) - General Information

Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen (CEA) covalently labeled with Technitium 99. The molecule has a molecular weight of ~54,000 Daltons.

 

Pharmacology of CEA-Scan (Immunomedics Inc)

Binds to the carcinoembryonic antigen, which is a cell surface protein generally overexpressed in colon (and other) cancers. The radioactive Tc99, which is covalently attached to the antibody, allows radiodiagnostic detection of CEA expressing cells and tumors

 

Additional information about CEA-Scan (Immunomedics Inc)

CEA-Scan (Immunomedics Inc) Indication: For imaging colorectal tumors Mechanism Of Action: Binds selectively to cell-surface carcinoembryonic antigen (CEA) expressed on colorectal tumors. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Arcitumomab Synonyms: CEA-Scan Drug Category: Diagnostic Agents; Imaging Agents Drug Type: Biotech; Approved; Investigational Other Brand Names containing Arcitumomab: CEA-Scan (Immunomedics Inc); Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Most likely removed by opsonization via the reticuloendothelial system, or by human antimurine antibody production Half Life: ~1 hours Dosage Forms of CEA-Scan (Immunomedics Inc): Not Available Chemical IUPAC Name: AntiCEA antibody Chemical Formula: C6398H9900N1714O1995S54 Arcitumomab on Wikipedia: https://en.wikipedia.org/wiki/Arcitumomab Organisms Affected: Not Available